S. Fontaine-Carbonel

G.O.19 Results of a phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3–25 years old spinal muscular atrophy patients

E. Mercuri, F. Muntoni, F. Rivier, 2014, Neuromuscular Disorders.